In 2023, Germany led global obstructive airway disease medicine sales at $37.2 per capita, followed by Iceland ($32.8) and Denmark ($32.4). Year-on-year variations reveal significant growth in Costa Rica at 8.45%, followed by Iceland at 4.92%, while Ireland and Slovakia saw declines of -1.97% and -0.81% respectively. Over the past five years, Germany showed consistent growth with a CAGR of approximately 3.58%, outpacing other countries.
Future Trends to Watch: With increasing prevalence of respiratory diseases and advancements in therapeutic treatments, expect growth in emerging markets and the adoption of biologics. Monitoring regulatory changes and healthcare policies will also be crucial for anticipating shifts in global sales distribution.
Top countries in Obstructive Airway Diseases Medicine Sales by Country
| # | 10 Countries | US Dollars PPP Per Capita | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Germany | 37.2 | 2023 | +2.2% | +3.58% | View data |
| 2 | 2 Iceland | 32.8 | 2023 | +0.61% | +4.92% | View data |
| 3 | 3 Denmark | 32.4 | 2023 | +0.93% | +1.02% | View data |
| 4 | 4 Italy | 28.4 | 2023 | +1.43% | +3.17% | View data |
| 5 | 5 Ireland | 23.9 | 2023 | -3.24% | -1.97% | View data |
| 6 | 6 Australia | 20.4 | 2023 | +0.99% | +3.47% | View data |
| 7 | 7 Finland | 19.9 | 2023 | +0.51% | 0% | View data |
| 8 | 8 Slovakia | 14.5 | 2023 | +1.4% | -0.81% | View data |
| 9 | 9 Latvia | 11.2 | 2023 | 0% | +2.29% | View data |
| 10 | 10 South Korea | 8 | 2023 | +1.27% | +0.25% | View data |
